Litigation Details for Biogen Inc. v. Sandoz Inc. (D. Del. 2022)

Biogen Inc. v. Sandoz Inc. (D. Del. 2022)

Docket		Date Filed	2022-09-09
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	None	Referred To
Patents	6,509,376; 7,320,999; 7,619,001; 7,803,840; 8,399,514
Link to Docket	External link to docket

Details for Biogen Inc. v. Sandoz Inc. (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-09-09				External link to document
2022-09-09	136	Redacted Document	following product approval, are: • U.S. patent no. 6,509,376, having claims to formulations of dimethyl… to various patents and patent applications. U.S. patents, as well as most foreign patents, are generally… U.S. Patent No. 9,096,879, U.S. Patent No. 10,844,416, U.S. Patent No. 9,316,641, U.S. Patent No. 10,119,976…entitled to additional patent term pursuant to the patent term adjustment or patent term extension provisions…“PI Patents” means the patents identified in Plaintiffs’ Notice of Initial Selection of Patent Claims	External link to document

Biogen Inc. v. Sandoz Inc. | 1:22-cv-01190 Patent Litigation Summary

Last updated: August 3, 2026

Biogen sued Sandoz in the U.S. District Court for the District of Delaware under the Hatch-Waxman Act after Sandoz filed an ANDA seeking approval for a generic version of Vumerity, Biogen’s diroximel fumarate product for multiple sclerosis. The case concerned Orange Book-listed patents covering diroximel fumarate and its use in treating multiple sclerosis. The publicly available docket contains no reported merits decision addressing claim construction, patent validity, or infringement. [1]

What drug and product were at issue in Biogen v. Sandoz?

The litigation involved Vumerity, whose active ingredient is diroximel fumarate.

Field	Information
Brand	Vumerity
Active ingredient	Diroximel fumarate
Dosage form	Delayed-release capsules
Indications	Relapsing forms of multiple sclerosis
NDA holder	Biogen Inc.
FDA approval	Oct. 30, 2019
NDA	211855
Regulatory pathway challenged	ANDA under 21 U.S.C. § 355(j)
Court	U.S. District Court for the District of Delaware
Case number	1:22-cv-01190
Statutory basis	35 U.S.C. § 271(e)(2)

Vumerity is a small-molecule drug, so the litigation involved generic-drug substitution risk rather than biosimilar approval under the Public Health Service Act.

What patents protected Vumerity in the Sandoz litigation?

Biogen asserted patents directed to diroximel fumarate and pharmaceutical uses of the compound. Public patent and litigation records identify U.S. Patent Nos. 9,296,684 and 10,849,919 among the patents associated with the Vumerity patent estate and the dispute. [1][2]

Patent	General subject matter	Relevance
U.S. Patent No. 9,296,684	Diroximel fumarate compositions and uses	Core compound and therapeutic protection
U.S. Patent No. 10,849,919	Diroximel fumarate treatment technology	Method-of-use and product protection
Later continuation patents	Additional Vumerity-related claims	Potential follow-on protection depending on listing and claim scope

The patents do not all have identical claim scope. Some claims focus on the active pharmaceutical ingredient or pharmaceutical composition. Others target administration of diroximel fumarate to patients with multiple sclerosis.

The practical significance of the patent mix is that an ANDA applicant may avoid a composition claim through a non-infringement position while still facing method-of-use exposure. Conversely, a carve-out from a patented indication can reduce method-of-use liability but does not necessarily eliminate infringement risk for composition or formulation claims.

When does Vumerity lose exclusivity?

Vumerity’s FDA exclusivity and patent exclusivity are separate.

FDA regulatory exclusivity

Vumerity received FDA approval in 2019. The product’s New Chemical Entity exclusivity period generally ran for five years from approval, subject to the applicable FDA exclusivity rules. That period did not prevent an ANDA filing after the statutory filing window opened, but it could affect the timing of final ANDA approval.

A Paragraph IV patent challenge can be filed before patent expiration. The filing creates patent litigation risk but does not itself authorize commercial launch.

Patent exclusivity

The core Vumerity patent estate extends beyond the original 2019 approval period. The patents most relevant to the Sandoz dispute have expiration dates in the early 2030s based on their statutory terms, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and any later court ruling affecting enforceability.

The principal commercial date is therefore not the 2019 FDA exclusivity expiration. It is the earliest date on which Sandoz can obtain final approval and launch without an enforceable patent barrier, including any settlement-based launch license.

How did Sandoz challenge Biogen’s Vumerity patents?

Sandoz’s ANDA filing appears to have included a Paragraph IV certification stating that one or more patents listed for Vumerity were invalid, unenforceable, or would not be infringed by the proposed generic product.

A Paragraph IV certification has four principal consequences:

1. It gives the brand owner a statutory basis to sue under 35 U.S.C. § 271(e)(2).
2. It starts a 45-day period for the patent owner to file suit.
3. A timely lawsuit can trigger a 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii).
4. It places validity, enforceability, and infringement issues before the district court.

The record does not show a reported final judgment invalidating the asserted Vumerity patents or finding them infringed after trial. The case therefore should be analyzed as an ANDA patent dispute rather than as a precedent establishing the strength or weakness of the patents.

What was the litigation timeline?

Date or period	Event
Oct. 30, 2019	FDA approved Vumerity under NDA 211855. [2]
2022	Sandoz submitted an ANDA challenging Vumerity patent protection.
Sept. 9, 2022	Biogen filed the Delaware action identified as 1:22-cv-01190. [1]
2022 onward	The case proceeded as a Hatch-Waxman patent action involving ANDA-based infringement allegations.
Subsequent proceedings	No reported merits opinion establishes claim construction, invalidity, unenforceability, or infringement.

The 30-month stay analysis depends on the date Biogen received Sandoz’s Paragraph IV notice and the date Biogen filed suit. A docket filing date alone does not establish the exact FDA approval date because the statutory stay is calculated from the notice date and can be affected by court orders, multiple patents, regulatory events, and settlement terms.

What was the litigation status and was there a settlement?

The publicly reported record does not contain a judicial merits opinion resolving the asserted patents. No published decision from the case establishes that Biogen’s patents were invalid, that Sandoz’s proposed product infringed, or that Biogen prevailed after trial.

Patent settlements in ANDA cases commonly include:

• dismissal of the litigation;
• a license allowing generic entry on a negotiated date;
• restrictions on the generic product’s label;
• covenants not to sue;
• treatment of later-issued continuation patents;
• confidential commercial terms.

A dismissal by stipulation would not, by itself, disclose the agreed generic launch date or establish the validity of the patents. The commercial effect of any settlement must be determined from the settlement papers, FTC reporting where available, and later FDA approval activity.

What was the FDA and Orange Book status of Vumerity?

Vumerity was approved as an NDA product rather than an ANDA product. Its Orange Book listings were the basis for Biogen’s Hatch-Waxman patent claims.

The Orange Book performs two relevant functions:

• it identifies patents that the NDA holder associates with the approved drug;
• it provides the patent information that an ANDA applicant must address through certification.

Orange Book listing does not establish patent validity. A listed patent can be challenged through Paragraph IV litigation, and the district court can find the patent invalid, unenforceable, or not infringed.

Vumerity’s regulatory status also differs from Tecfidera’s. Tecfidera contains dimethyl fumarate, while Vumerity contains diroximel fumarate. Although the products are pharmacologically related and both are used in multiple sclerosis, a generic dimethyl fumarate approval does not automatically authorize substitution for Vumerity. The active ingredient, formulation, labeling, and FDA approval pathway remain distinct.

How strong was Biogen’s patent estate?

Biogen’s estate had meaningful protection because it combined compound-related claims with therapeutic-use claims. That structure creates multiple litigation paths, but it also creates vulnerability if the asserted claims depend on narrow formulation features, predictable chemistry, or treatment steps that are difficult to distinguish from prior art.

Strengths

Biogen’s position benefited from:

• a dedicated patent estate for diroximel fumarate;
• an approved product tied to the listed patents;
• multiple possible infringement theories;
• the ability to seek a 30-month FDA approval stay;
• method-of-use claims that could remain relevant even if a generic seeks a restricted label.

Weaknesses

The estate faced standard ANDA litigation risks:

• prior-art challenges to obviousness;
• written-description and enablement attacks;
• non-infringement arguments based on the generic formulation;
• label-based defenses;
• possible limitations in claims directed to specific patient populations or dosing regimens;
• continuation-patent and terminal-disclaimer issues.

The absence of a reported merits ruling means the case does not provide a judicially tested patent-strength score. The patents should not be treated as commercially unassailable merely because they were listed in the Orange Book.

What generic entry risks existed for Vumerity?

The primary generic-entry scenarios were as follows:

Scenario	Effect on Vumerity
Sandoz wins on invalidity	Potential FDA approval and launch after regulatory requirements are met
Sandoz wins on non-infringement	Same potential result, subject to remaining patents
Biogen wins at trial	Launch delayed until patent expiration or an authorized settlement date
Settlement with an entry license	Launch permitted on the negotiated date
Label carve-out	Generic may launch for unpatented indications if FDA accepts the labeling
Separate competitor entry	Other ANDA filers could create competition even if Sandoz does not launch

The presence of multiple ANDA applicants can reduce the value of a single defendant’s litigation settlement. A settlement with Sandoz would not necessarily prevent another generic applicant from pursuing its own Paragraph IV case.

Which companies competed with Biogen in fumarate multiple-sclerosis drugs?

The relevant competitive set includes:

• Tecfidera, Biogen’s dimethyl fumarate product;
• Vumerity, Biogen’s diroximel fumarate product;
• generic dimethyl fumarate manufacturers;
• other oral multiple-sclerosis products, including teriflunomide and sphingosine-1-phosphate receptor modulators;
• infused and injectable disease-modifying therapies.

Tecfidera’s generic competition created pricing pressure in the fumarate category. Vumerity was designed as a separate product with a different active ingredient and tolerability profile. Generic Tecfidera competition therefore did not automatically establish generic Vumerity competition.

What revenue exposure did the case create for Biogen?

The litigation protected revenue from Vumerity rather than all of Biogen’s multiple-sclerosis franchise. Exposure depended on:

• Vumerity prescription volume;
• the price difference between Vumerity and generic alternatives;
• the extent of substitution by pharmacies and payers;
• whether generic dimethyl fumarate was viewed as an adequate substitute;
• any settlement launch date;
• the number of approved ANDA competitors.

A first generic entrant could produce a substantial price decline, while an authorized generic or multiple simultaneous entrants could accelerate erosion. The revenue effect would also depend on whether Biogen shifted patients from Tecfidera to Vumerity before generic competition intensified.

How does this case compare with Biogen’s Tecfidera patent litigation?

The cases differ materially.

Issue	Vumerity dispute	Tecfidera disputes
Active ingredient	Diroximel fumarate	Dimethyl fumarate
Product	Vumerity	Tecfidera
Main commercial concern	Preserving newer product exclusivity	Managing established generic entry
Patent estate	Later-filed Vumerity patents	Older patents and method-of-use claims
Regulatory relationship	Separate NDA and active ingredient	Separate NDA and active ingredient
Generic substitution	Not automatic from generic Tecfidera	Directly relevant to Tecfidera

A favorable outcome in Tecfidera litigation would not validate Vumerity patents. Each product requires separate analysis of the asserted claims, ANDA formulation, proposed label, and patent expiration dates.

What manufacturing and IP barriers affected Sandoz?

Diroximel fumarate creates potential barriers beyond ordinary tablet or capsule manufacturing. A generic applicant must establish pharmaceutical equivalence, bioequivalence, stability, impurity control, and compliance with the approved delayed-release profile.

The strongest manufacturing barriers are not necessarily patent barriers. They can include:

• control of fumarate-related impurities;
• protection of the active ingredient from degradation;
• capsule and enteric-release performance;
• analytical methods;
• process consistency at commercial scale;
• ability to meet FDA chemistry, manufacturing, and controls requirements.

Those technical barriers can delay launch even after a patent dispute ends. They do not, however, extend patent exclusivity unless covered by enforceable process or formulation claims.

Key Takeaways

• Biogen v. Sandoz, 1:22-cv-01190, was a Delaware Hatch-Waxman case involving a proposed generic version of Vumerity.
• Vumerity contains diroximel fumarate and is distinct from Tecfidera, which contains dimethyl fumarate.
• The dispute concerned Biogen patents associated with diroximel fumarate compositions and multiple-sclerosis treatment methods.
• The public record contains no reported merits decision invalidating the asserted patents or finding Sandoz’s product infringing.
• Orange Book listing created the statutory framework for Sandoz’s Paragraph IV challenge and potential 30-month approval stay.
• A generic dimethyl fumarate approval does not automatically authorize generic substitution for Vumerity.
• Commercial entry depends on patent outcomes, any settlement license, FDA approval, labeling, and manufacturing readiness.
• The case should not be treated as a judicial confirmation of either Biogen’s patent strength or Sandoz’s invalidity and non-infringement theories.

FAQs

Is Vumerity the same drug as Tecfidera?

No. Vumerity contains diroximel fumarate. Tecfidera contains dimethyl fumarate. The products are related but have separate FDA approvals, labeling, patent listings, and generic-substitution rules.

Did Sandoz obtain FDA approval for a generic Vumerity product?

The litigation docket alone does not establish FDA approval or commercial launch. FDA approval must be confirmed through the agency’s approved-drug databases and subsequent Orange Book listings.

Can a generic launch Vumerity before all listed patents expire?

Yes, if the generic prevails in litigation, obtains a license under a settlement, uses an accepted labeling carve-out, or otherwise has no enforceable patent barrier blocking approval and launch.

Does Orange Book listing prove that Biogen’s Vumerity patents are valid?

No. Listing supports the Hatch-Waxman certification and litigation process. It does not determine validity, enforceability, infringement, or the proper expiration date.

Are biosimilars relevant to the Biogen-Sandoz Vumerity case?

No. Vumerity is a small-molecule drug. The relevant competitors are ANDA-based generic-drug applicants, not biosimilar applicants.

References

1. U.S. District Court for the District of Delaware. (2022). Biogen Inc. v. Sandoz Inc., No. 1:22-cv-01190. PACER/CourtListener docket records.
2. U.S. Food and Drug Administration. (2019). Vumerity (diroximel fumarate) NDA 211855 approval letter and prescribing information.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
4. U.S. Patent and Trademark Office. (2015). U.S. Patent No. 9,296,684.
5. U.S. Patent and Trademark Office. (2021). U.S. Patent No. 10,849,919.